FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2505105343> ?p ?o ?g. }

• W2505105343 endingPage "788" @default.
• W2505105343 startingPage "778" @default.
• W2505105343 abstract "A number of policy and labeling interventions aimed at reducing inappropriate prescribing of erythropoiesis-stimulating agents (ESAs) were implemented in the U.S. between 2006 and 2010. These interventions included the addition of an FDA Black Box Warning to ESA labeling, the implementation of a Risk Evaluation and Mitigation Strategy program, and the adoption of payment restrictions by the Centers for Medicare and Medicaid Services (CMS). The impact of these safety interventions on different types of ESA prescribing (on-label, off-label; evidence-based, not evidence-based) has not been investigated in a single study. The objective of this study was to explore the prescribing patterns of ESAs for on- and off-label indications in the U.S. hospital inpatients during the period of major policy and labeling changes. A retrospective analysis of ESAs utilization patterns was conducted using Cerner Health Facts® database from January 1, 2005 to June 30, 2011. The study population consisted of adult patients admitted to hospitals during the study period who received at least one ESAs order. Indications for ESA use were assigned based on ICD-9 CM diagnosis codes, procedure codes, and medication records. ESA use was then classified based on FDA-approval and the strength of scientific evidence supporting its use. Indication categories included (1) on-label use (ONS); (2) off-label use, supported (OFS); and (3) off-label use, unsupported (OFU). Descriptive statistics were used to examine ESA use by patient, hospital, and physician characteristics and over time. ESAs were most frequently prescribed for ONS (48.7%), followed by OFU (42.7%) and OFS indications (8.6%). Of all off-label use, 83.2% were for unsupported indications. Between 2005 and 2010, the percent of inpatient visits with ESA use decreased for supported indications, both on-label (−63.2%) and off-label (−78.2%), but increased for unsupported indications (80%). OFU use surpassed ONS use as the most common type of ESA use in 2009. Total and ONS ESA use decreased markedly, while OFU ESA use continued to increase during the period of major policy and labeling changes." @default.
• W2505105343 created "2016-08-23" @default.
• W2505105343 creator A5070467550 @default.
• W2505105343 creator A5079259723 @default.
• W2505105343 creator A5083685453 @default.
• W2505105343 creator A5090209503 @default.
• W2505105343 date "2017-07-01" @default.
• W2505105343 modified "2023-10-03" @default.
• W2505105343 title "On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes" @default.
• W2505105343 cites W1581588655 @default.
• W2505105343 cites W1750927530 @default.
• W2505105343 cites W1980954968 @default.
• W2505105343 cites W1983560550 @default.
• W2505105343 cites W1992356976 @default.
• W2505105343 cites W1997101969 @default.
• W2505105343 cites W2026162633 @default.
• W2505105343 cites W2034235224 @default.
• W2505105343 cites W2039169204 @default.
• W2505105343 cites W2041738951 @default.
• W2505105343 cites W2051875958 @default.
• W2505105343 cites W2065837924 @default.
• W2505105343 cites W2067416482 @default.
• W2505105343 cites W2072509148 @default.
• W2505105343 cites W2078118224 @default.
• W2505105343 cites W2093499113 @default.
• W2505105343 cites W2107853873 @default.
• W2505105343 cites W2110936793 @default.
• W2505105343 cites W2121217569 @default.
• W2505105343 cites W2121454917 @default.
• W2505105343 cites W2121487587 @default.
• W2505105343 cites W2133914089 @default.
• W2505105343 cites W2154367023 @default.
• W2505105343 cites W2154560753 @default.
• W2505105343 cites W2157335205 @default.
• W2505105343 cites W2158183352 @default.
• W2505105343 cites W2165752285 @default.
• W2505105343 cites W2171049004 @default.
• W2505105343 cites W2320453390 @default.
• W2505105343 cites W2980284346 @default.
• W2505105343 cites W1906914909 @default.
• W2505105343 cites W3149132779 @default.
• W2505105343 doi "https://doi.org/10.1016/j.sapharm.2016.07.005" @default.
• W2505105343 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27595426" @default.
• W2505105343 hasPublicationYear "2017" @default.
• W2505105343 type Work @default.
• W2505105343 sameAs 2505105343 @default.
• W2505105343 citedByCount "5" @default.
• W2505105343 countsByYear W25051053432019 @default.
• W2505105343 countsByYear W25051053432021 @default.
• W2505105343 countsByYear W25051053432022 @default.
• W2505105343 crossrefType "journal-article" @default.
• W2505105343 hasAuthorship W2505105343A5070467550 @default.
• W2505105343 hasAuthorship W2505105343A5079259723 @default.
• W2505105343 hasAuthorship W2505105343A5083685453 @default.
• W2505105343 hasAuthorship W2505105343A5090209503 @default.
• W2505105343 hasConcept C10138342 @default.
• W2505105343 hasConcept C105795698 @default.
• W2505105343 hasConcept C144133560 @default.
• W2505105343 hasConcept C145097563 @default.
• W2505105343 hasConcept C159110408 @default.
• W2505105343 hasConcept C160735492 @default.
• W2505105343 hasConcept C162324750 @default.
• W2505105343 hasConcept C188313352 @default.
• W2505105343 hasConcept C194828623 @default.
• W2505105343 hasConcept C27415008 @default.
• W2505105343 hasConcept C2776534028 @default.
• W2505105343 hasConcept C2908647359 @default.
• W2505105343 hasConcept C33923547 @default.
• W2505105343 hasConcept C39896193 @default.
• W2505105343 hasConcept C50522688 @default.
• W2505105343 hasConcept C512399662 @default.
• W2505105343 hasConcept C545542383 @default.
• W2505105343 hasConcept C71924100 @default.
• W2505105343 hasConcept C98274493 @default.
• W2505105343 hasConcept C99454951 @default.
• W2505105343 hasConceptScore W2505105343C10138342 @default.
• W2505105343 hasConceptScore W2505105343C105795698 @default.
• W2505105343 hasConceptScore W2505105343C144133560 @default.
• W2505105343 hasConceptScore W2505105343C145097563 @default.
• W2505105343 hasConceptScore W2505105343C159110408 @default.
• W2505105343 hasConceptScore W2505105343C160735492 @default.
• W2505105343 hasConceptScore W2505105343C162324750 @default.
• W2505105343 hasConceptScore W2505105343C188313352 @default.
• W2505105343 hasConceptScore W2505105343C194828623 @default.
• W2505105343 hasConceptScore W2505105343C27415008 @default.
• W2505105343 hasConceptScore W2505105343C2776534028 @default.
• W2505105343 hasConceptScore W2505105343C2908647359 @default.
• W2505105343 hasConceptScore W2505105343C33923547 @default.
• W2505105343 hasConceptScore W2505105343C39896193 @default.
• W2505105343 hasConceptScore W2505105343C50522688 @default.
• W2505105343 hasConceptScore W2505105343C512399662 @default.
• W2505105343 hasConceptScore W2505105343C545542383 @default.
• W2505105343 hasConceptScore W2505105343C71924100 @default.
• W2505105343 hasConceptScore W2505105343C98274493 @default.
• W2505105343 hasConceptScore W2505105343C99454951 @default.
• W2505105343 hasIssue "4" @default.
• W2505105343 hasLocation W25051053431 @default.
• W2505105343 hasLocation W25051053432 @default.

• next